What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder

© Provided by Benzinga Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) presented interim data from the ongoing Phase 2 GATEWAY study of ARO-ANG3, the company's investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease. The company is planning a Phase 3 study to investigate ARO-ANG3 further and intends to meet with regulatory authorities in 2H of 2023 to discuss the proposed study design.

Trending: A Father Paid $21,000 For His Daughter To See Taylor Swift After He Didn't Receive His Initial $1,900 Tic

Must Read: Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use

See Also: Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars. At study week 20, administration of 200 mg or 300 mg ARO-ANG3 on day one and day 84 led to the following changes: Mean reductions in LDL-C (Martin-Hopkins) of 48.1% and 44.0%, respectively. ANPTL3 inhibition with ARO-ANG3 also reduced HDL-C, non-HDL-C, and triglycerides, consistent with published human genetic data Overall, no newly identified patterns of adverse events in HoFH patients. One serious adverse event of the second-degree atrioventricular block was reported in a patient with extensive atherosclerotic cardiovascular disease history, considered unrelated to ARO-ANG3. ARWR Price Action: Arrowhead Pharmaceuticals shares are down 0.19% at $36.40 at publication Tuesday.

Read Next: Goldman Sachs Turns Bullish On Biotech With 'Significant Opportunity'

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

This article What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder originally appeared on Benzinga.com.